Jensa Morris: Why Low Molecular Weight Heparins Should Be the First Choice for VTE
Jensa Morris, Director of Smilow Hospitalist Service at Yale New Haven Hospital, shared a post on LinkedIn about a recent article by Youssef Saklawi et al, published in Journal of Hospital Medicine, adding:
“There are so many clinical interventions that we do reflexively despite a mountain of clinical evidence to the contrary.
Thank you Journal of Hospital Medicine and TWDFNR for reminding us that LMWH and not UFH should be first choice for patients requiring non-oral treatment for VTE, even for those who may later require thrombolysis or thrombectomy.”
Title: Things we do for no reason™: Routine use of unfractionated heparin for initial anticoagulation in venous thromboembolism
Authors: Youssef Saklawi, Mohamad Ali Tfaily, Bhargav Marthambadi, Adrian Umpierrez
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering